Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), according to a multicenter study led by the Hospital del Mar Research ...

Please provide your email address to receive an email when new articles are posted on . “It has long been recognized that patients with RA suffer more frequent heart attacks and strokes,” Daniel ...

A key opinion leader considers the optimal timing of adding an SGLT2 inhibitor to the treatment for patients with heart failure. John McMurray, MBChB: SGLT2 inhibitors are the most recent development ...

PHILADELPHIA – Combination of the KRAS inhibitor sotorasib (Lumakras) with afatinib, a pan-ErbB tyrosine kinase inhibitor, was feasible in treating non-small cell lung cancer (NSCLC) patients with ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The combination ...

The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...

Adding the menin inhibitor revumenib (Revuforj) to azacitidine and venetoclax (Venclexta) seemed to benefit older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia ...

Phase I/feasibility trial of dose-dense carboplatin (C) and paclitaxel (P) in patients (pts) with ovarian cancer: A Gynecologic Oncology Group study No significant financial relationships to disclose.

PARP inhibitors are not only expanding the field of prostate cancer but they're giving men another option for life after cancer. The mainstay of treatment for metastatic prostate cancer has long ...

The "TGFb inhibitors – Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com’s offering. The companies and academics are working to assess challenges and seek opportunities ...